Exploiting the p53 Pathway for Therapy
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The excitement around the entry into the clinic of the first generation of p53-specific drugs has become muted as the hoped-for dramatic clinical responses have not yet been seen. However, these pioneer molecules have become exceptionally powerful tools in the analysis of the p53 pathway and, as a result, a whole spectrum of new interventions are being explored. These include entirely novel and innovative approaches to drug discovery, such as the use of exon-skipping antisense oligonucleotides and T-cell-receptor-based molecules. The extraordinary resources available to the p53 community in terms of reagents, models, and collaborative networks are generating breakthrough approaches to medicines for oncology and also for other diseases in which aberrant p53 signaling plays a role.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 2×
“…found to be selectively up-regulated by mutant p53, and mutant p53 expression was required to maintain the prometastatic phenotype of the murine model of pancreatic cancer, which is a highly metastatic cancer that is frequently linked with p53 mutations (Morton et al. 2010; Waddell et al. 2015).”
BackgroundImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261 · cited 1×
“Third, cellular thermal shift assay (CETSA)-based mass spectroscopy methods allow the whole proteome to be examined for targets of small-molecule drugs with unequaled precision (Martinez Molina et al. 2013; Martinez Molina and Nordlund 2015).”
MethodTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 2×
“Under normal conditions, p53 promotes antioxidant activities by controlling the expression of various metabolic enzymes, including those that promote the pentose phosphate pathway (PPP) and, hence, increase the production of NADPH.”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · cited 2×
“…oxidation provides a source of energy and ATP generation through OXPHOS (oxidative phosphorylation) in p53-proficient cells to maintain viability (Kruiswijk et al. 2015). p53deficient cells, however, are more vulnerable to energy fluctuations as a result of being less able to use other…”
BackgroundDNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD
Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V., & Chumakov, P. M. (2004) · Science · doi:10.1126/science.1095569 · Cited by 731
Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002459107 · Cited by 705
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 2×
“This may explain why Nutlin is able to induce the accumulation of p53 in normal mouse tissue (Goh et al. 2015) but the MI-219 compound cannot (Shangary et al. 2008).”
BackgroundMutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · cited 4×
“…in genotoxicity in the p53-deficient cells toward radiation and different genotoxic agents, including cisplatin, campthothecin, and doxorubicin, as a consequence of the combined loss of G1 and G2/M checkpoints (Russell et al. 1995; Wang et al. 1996; Nghiem et al. 2001, 2002; Reaper et al. 2011).”
BackgroundInfluentialMutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 1×
“A recent example is the inhibition of PDGFRb by the FDA-approved agent imatinib that, as a single agent, led to the striking reduction of tumor metastases in a mouse model of pancreatic ductal adenocarcinoma, which expresses p53R172H (Weissmueller et al. 2014).”
BackgroundToledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465 · cited 1×
“Similarly, genetic deletion of ATM or inhibition of ATM and ATR kinases potently sensitizes p53-deficient cells to a range of genotoxic agents (Fedier et al. 2003; Jiang et al. 2009; Toledo et al. 2011).”
BackgroundUCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453 · cited 2×
“…in genotoxicity in the p53-deficient cells toward radiation and different genotoxic agents, including cisplatin, campthothecin, and doxorubicin, as a consequence of the combined loss of G1 and G2/M checkpoints (Russell et al. 1995; Wang et al. 1996; Nghiem et al. 2001, 2002; Reaper et al. 2011).”
BackgroundTranslating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · cited 1×
“In response to DNA damage, p53 induces a G1-dependent cell-cycle arrest, which is primarily mediated by a p21-induced response, and may prevent cells from undergoing further damage in S or G2/M phases, thus attenuating the toxicity of S phase or mitotic poisons (Cheok et al. 2010a,b).”
BackgroundSelf-citationLi, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · cited 2×
“A number of such molecules have been described, including the combination of HSP90 inhibitors with histone deacetylase inhibitors, which have been shown to act by destabilizing mutant p53 despite quite pelitropic action (Li et al. 2011a,b).”
BackgroundTargeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290 · cited 2×
“…in genotoxicity in the p53-deficient cells toward radiation and different genotoxic agents, including cisplatin, campthothecin, and doxorubicin, as a consequence of the combined loss of G1 and G2/M checkpoints (Russell et al. 1995; Wang et al. 1996; Nghiem et al. 2001, 2002; Reaper et al. 2011).”
BackgroundTovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · cited 1×
“Although SJSA-1 cells die when exposed to Nutlin or other human MDM2 inhibitors (HDMi), many p53 wildtype human cancer cells show a growth arrest response that is reversible rather than cell death under similar conditions of exposure (Tovar et al. 2013; Allen et al. 2014).”
BackgroundVikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145 · cited 2×
“In tissue culture models, small hairpin RNA (shRNA) knockdown of mutant p53 expression induces apoptosis (Vikhanskaya et al. 2007) and, most recently in an in vivo model, the tumor-specific inactivation of mutant p53 expression led to tumor growth inhibition apoptosis and extended survival.”
BackgroundValidation of MdmX as a therapeutic target for reactivating p53 in tumors
Garcia, D., Warr, M. R., Martins, C. P., Brown Swigart, L., Passegué, E., & Evan, G. I. (2011) · Genes & Development · doi:10.1101/gad.16722111 · Cited by 83 · cited 2×
“In some sys- tems, Mdm4 appears as a safer target as it is amplified to high levels in only a subset of human cancers, and mouse models of genetic ablation suggest that inhibiting Mdm4 would be less toxic than inhibiting Mdm2 (Garcia et al. 2011).”
BackgroundHiraki, M., Hwang, S.-Y., Cao, S., Ramadhar, T. R., Byun, S., Yoon, K. W., Lee, J. H., Chu, K., Gurkar, A. U., Kolev, V., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.07.016 · Cited by 81
Cited by
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Metadata
- Authors
- Cheok, C. F., & Lane, D. P.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-02-13
- Volume
- 7
- Issue
- 3
- Pages
- a026310
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2588020180
- Cited by
- 52
- References
- 24
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.